Abstract
Combinations of trastuzumab with either docetaxel or vinorelbine are considered valuable treatment options for HER2-positive metastatic breast cancer patients. We performed a retrospective comparison of the clinical outcomes associated with either one of these combinations. From a multi-institutional database we retrieved 179 patients treated with either docetaxel or vinorelbine plus trastuzumab as first-line therapy for HER2-positive advanced breast cancer. Docetaxel-trastuzumab was superior to vinorelbine-trastuzumab in terms of response rate (RR: 77 vs 57%, p = 0.01) and median overall survival (OS: 35 vs 23 months, p = 0.04), but not in median time to progression (TTP: 12 vs 10 months, p = 0.53). At multivariate analysis, type of treatment was not associated with TTP but was an independent predictor of OS, with a significant reduction in the risk of death in favor of docetaxel-trastuzumab (HR 0.474, 95% IC 0,303-0.742, p < 0.01). Docetaxel or vinorelbine, when combined with trastuzumab, provide excellent rates of tumor control in patients with previously untreated HER2-positive advanced breast cancer. Docetaxel may offer some advantage in terms of response rate and resulted in a significantly prolonged overall survival, whi...Continue Reading
References
Jan 1, 1981·Cancer·A B MillerA Winkler
Jan 1, 1995·Investigational New Drugs·D J Adams, V C Knick
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FumoleauM T Closon
Mar 15, 2001·The New England Journal of Medicine·D J SlamonL Norton
May 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H J BursteinE P Winer
Feb 15, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A DepierreV Trillet-Lenoir
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harold J BursteinEric P Winer
Dec 19, 2003·Expert Opinion on Pharmacotherapy·Filippo MontemurroMassimo Aglietta
Mar 20, 2004·Oncology·Filippo MontemurroMassimo Aglietta
May 20, 2004·Journal of the National Cancer Institute·Mark D PegramDennis J Slamon
May 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michel MartyJean-Marc Extra
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 21, 2005·The New England Journal of Medicine·Edward H RomondNorman Wolmark
Feb 14, 2006·Cancer Treatment Reviews·Max Mano
Feb 24, 2006·The New England Journal of Medicine·Heikki JoensuuUNKNOWN FinHer Study Investigators
Sep 14, 2006·British Journal of Cancer·A ChanUNKNOWN Navelbine Herceptin Project
Feb 1, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A Chan
Jul 7, 2007·Cancer·Harold J BursteinEric P Winer
Sep 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C CataniaF Nolè
Jul 3, 2008·Anti-cancer Drugs·Nahomi TokudomeShigemitsu Takashima
Citations
Feb 9, 2011·Medical Oncology·Yan-Xia ShiDong-Geng Liu
Sep 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A AwadaE Staroslawska
Sep 23, 2014·Investigational New Drugs·Hirofumi MukaiYasutsuna Sasaki
Dec 21, 2011·Current Medical Research and Opinion·Mahmut GümüşKarim A Benhadji
May 17, 2011·Clinical Breast Cancer·Barry MirtschingMyo Min
Jan 17, 2013·The Breast Journal·Ying-Chun XuFeng-Chun Zhang
Jul 10, 2014·ISRN Oncology·Athina StravodimouIoannis A Voutsadakis
Jul 16, 2014·Clinical Breast Cancer·Sharon WilksLinda Vahdat
Aug 19, 2011·Journal of breast cancer·Yu Rim LeeHyuk-Chan Kwon
May 17, 2018·Anais Da Academia Brasileira De Ciências·Luma G MagalhaesAdriano D Andricopulo
Jan 13, 2021·Cancers·Faruque Azam, Alexei Vazquez